Eli Lilly and Company ($LLY) Stock Forecast: Down 5.6% Today

What is Eli Lilly and Company?

Eli Lilly and Company (LLY) is a pharmaceutical giant known for its innovative drugs in various therapeutic areas. Today, the stock experienced a significant bearish movement.

Why is Eli Lilly and Company going down?

LLY stock is down 5.6% on Mar 18, 2026 13:40

• Positive Phase 2 results reported by a competitor in oncology and immunology may have overshadowed Eli Lilly's performance, leading investors to shift their focus towards the competitor's promising pipeline.
• Mosaic's strategic move into rare earths extraction could have diverted investor attention away from traditional pharmaceutical stocks like Eli Lilly, impacting its stock price negatively.
• Livforsakringsbolaget Skandia Omsesidigt's decision to reduce its stake in Eli Lilly could have signaled concerns about the company's future growth prospects, contributing to the bearish movement.
• Overall, the combination of positive developments in other companies' pipelines and shifting investor sentiment towards different sectors may have influenced the bearish trend in Eli Lilly's stock today.

LLY Price Chart

LLY Technical Analysis

LLY News

Pfizer Phase 2 Wins Reshape Growth Story In Oncology And Immunology

Pfizer reported positive Phase 2 results for atirmociclib in advanced breast cancer and tilrekimig in moderate to severe atopic dermatitis, signaling progress in its oncology and immunology pipelines. These developments are crucial as Pfizer aims to rebuild its growth engine and diversify its product mix post-COVID, offering new high-value opportunities despite increased execution risks. The success of these programs in later stages and regulatory approval will be key for the company's medium-term earnings and competitive positioning against major pharmaceutical rivals.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/pfizer-phase-2-wins-reshape-growth-story-in-oncology-and-imm

Mosaic’s Rare Earths Bet Could Revalue the Stock: What That Means for Investors

Mosaic, traditionally a fertilizer company, saw its stock jump 10% after announcing a joint venture with Rainbow Rare Earths to extract neodymium and praseodymium from phosphogypsum waste in Brazil, targeting production by 2030. This move could significantly revalue the stock, as the rare earths market commands higher multiples due to geopolitical urgency to reduce China's dominance. While the project is still years from revenue and Mosaic faces antitrust probes and tariff pressure, the rare earths optionality is a key swing factor for investors.

https://247wallst.com/investing/2026/03/18/mosaics-rare-earths-bet-could-revalue-the-stock-what-that-means-for-investors/

Glaucoma trial tests cannabinoid pill designed to protect vision

Artelo Biosciences (NASDAQ: ARTL) is expanding into the $16.3 billion glaucoma market with a fully funded investigator-sponsored trial for its cannabinoid pill, ART27.13, aimed at protecting vision. The trial will evaluate ART27.13's efficacy in modulating intraocular pressure (IOP) and its neuroprotective properties without central nervous system side effects. This move diversifies Artelo's pipeline without shareholder dilution, capitalizing on a European patent protecting the ART27.13 formulation through 2041, with first patient enrollment expected in Q2 2026.

https://www.stocktitan.net/news/ARTL/vanderbilt-report-artelo-biosciences-expands-into-16-3-billion-06cu7r5zw29a.html

Heidelberg Materials gets Morgan Stanley double upgrade as carbon bet unwinds

Morgan Stanley has upgraded Heidelberg Materials to "overweight" from "underweight" and set a price target of €219, citing that the recent 30% selloff was due to unfounded fears about carbon pricing. The brokerage argues that carbon pricing has not been a primary driver of cement pricing in Europe, with free allowances covering most sector emissions. Morgan Stanley's analysis suggests that the current share price is too pessimistic, implying volume contraction, and forecasts higher EBIT estimates for FY26 and FY27 driven by cost programs and acquisitions.

https://www.investing.com/news/stock-market-news/heidelberg-materials-gets-morgan-stanley-double-upgrade-as-carbon-bet-unwinds-4567952

Livforsakringsbolaget Skandia Omsesidigt Trims Position in Eli Lilly and Company

Livforsakringsbolaget Skandia Omsesidigt, a Swedish hedge fund, reduced its stake in Eli Lilly and Company by 4.3% in the third quarter of 2026, selling 1,200 shares. The firm now holds 26,506 shares valued at $20.2 million, representing about 0.8% of its portfolio. This adjustment by an institutional investor can indicate shifting market sentiment regarding the pharmaceutical giant's future performance.

https://nationaltoday.com/us/in/indianapolis/news/2026/03/18/livforsakringsbolaget-skandia-omsesidigt-trims-position-in-eli-lilly-and-company/

Trending Today

Mosaic Company (The) ($MOS) Stock Forecast: Down 9.3% Today

QuantumScape Corp. ($QS) Stock Forecast: Down 5.5% Today

FuelCell Energy ($FCEL) Stock Forecast: Down 5.4% Today

Peloton Interactive Inc ($PTON) Stock Forecast: Down 5.7% Today

Kimco Realty Corporation ($KIM) Stock Forecast: Down 3.5% Today

SL Green Realty Corp ($SLG) Stock Forecast: Down 5.2% Today

StoneCo Ltd. ($STNE) Stock Forecast: Down 5.2% Today

Cleveland-Cliffs Inc. ($CLF) Stock Forecast: Down 5.0% Today

American Airlines Group Inc. ($AAL) Stock Forecast: Down 5.4% Today

TKO Group Holdings Inc ($TKO) Stock Forecast: Down 5.2% Today

Eli Lilly and Company Price History

03.01.2026 - LLY Stock was down 3.6%

• The promising Q4 revenue projections for Eli Lilly were overshadowed by the substantial investments in research and development. This financial strategy possibly instigated investor worries over the company's future profitability, contributing to the day's bearish market performance.
• Forecasts of positive stock momentum following the announcement of fresh data from Lilly's GLP-1 clinical trials failed to materialize as expected, potentially disappointing eager investors awaiting favorable outcomes.
• The noteworthy surge in institutional investors, with Peterson Wealth Services among them, signaled an optimistic long-term perspective on Eli Lilly. However, short-term profit-taking or apprehensions regarding R&D expenditures impacting immediate earnings might have influenced today's market downturn.

05.01.2026 - LLY Stock was down 5.2%

• The bearish movement in Eli Lilly & Co (LLY) stock could be attributed to profit-taking by investors after a recent rally or market correction.
• Despite being identified as a promising growth stock with strong fundamentals, including earnings and sales growth, investors might have reacted to broader market sentiment or sector-specific concerns.
• The focus on pharmaceutical stocks like Eli Lilly & Co (LLY) could have shifted due to a stem cell specialist going public via a SPAC merger, drawing attention away from traditional pharmaceutical companies.
• Additionally, a positive stock price prediction for Waste Management and growth potential for Hershey might have diverted investor interest away from Eli Lilly & Co (LLY) temporarily, impacting its stock performance.

05.01.2026 - LLY Stock was down 5.8%

• The decision by CVS Health to replace Amgen and Lilly's bone disease therapies with lower-cost biosimilars is likely to have negatively impacted Lilly's stock price, potentially decreasing revenue from these products.
• The market's response to Eikon Therapeutics' Nasdaq debut, despite an initial lower share price, might have shifted investor focus away from established pharmaceutical companies like Lilly, contributing to the bearish movement.
• CVS Health's emphasis on cost-effective alternatives over branded treatments could have prompted investor doubts regarding the competitiveness of Lilly's products, leading to the bearish trend.
• Overall, the transition towards more economical healthcare options and the introduction of new players in the pharmaceutical industry might have affected investor perception of established companies such as Eli Lilly, resulting in the bearish market movement.

18.02.2026 - LLY Stock was down 5.6%

• Positive Phase 2 results reported by a competitor in oncology and immunology may have overshadowed Eli Lilly's performance, leading investors to shift their focus towards the competitor's promising pipeline.
• Mosaic's strategic move into rare earths extraction could have diverted investor attention away from traditional pharmaceutical stocks like Eli Lilly, impacting its stock price negatively.
• Livforsakringsbolaget Skandia Omsesidigt's decision to reduce its stake in Eli Lilly could have signaled concerns about the company's future growth prospects, contributing to the bearish movement.
• Overall, the combination of positive developments in other companies' pipelines and shifting investor sentiment towards different sectors may have influenced the bearish trend in Eli Lilly's stock today.

28.00.2026 - LLY Stock was down 5.2%

• Profit-taking by investors post a period of strong performance could be a reason behind the bearish movement in LLY's stock.
• Market sentiment might have been influenced by broader economic factors or sector rotation, despite positive news regarding a strategic partnership for genetic biotech treatments targeting hearing loss.
• The FDA granting Breakthrough Therapy Designation to a competitor for treating cutaneous lupus erythematosus (CLE) might have diverted investor attention away from LLY, impacting its stock performance.
• Competition in the pharmaceutical industry, exemplified by positive Phase II results for an obesity candidate by a competitor, may have also played a role in the bearish movement in LLY's stock.

17.02.2026 - LLY Stock was down 5.2%

• Despite a recent increase, Eli Lilly's stock has encountered a downward trend, potentially linked to analysts' downgrade, hinting at challenges ahead.
• The launch of Eli Lilly's weight-loss pill, Orforglipron, might not be sufficient to counteract concerns arising from the downgrade.
• Positive results from Pfizer on their advanced CDK4 inhibitor, Atirmociclib, could have diverted investor attention to Pfizer's promising pipeline, impacting Eli Lilly's stock negatively.
• Investors could be reassessing Eli Lilly's competitive position in the pharmaceutical sector, especially compared to companies like Pfizer, with robust drug candidates like Atirmociclib.

17.02.2026 - LLY Stock was down 5.7%

• Eli Lilly's stock faced a bearish movement today following a series of downgrades from analysts, including concerns about valuation and emerging competitors in the oral GLP-1 market.
• Despite a strong run-up in the past year and the anticipation of the launch of its new weight-loss pill, orforglipron, later this year, the stock has been downgraded, indicating potential headwinds ahead.
• The downgrades come at a time when the pharmaceutical industry is seeing advancements from competitors, potentially impacting Eli Lilly's market position and growth prospects.
• The overall sentiment towards Eli Lilly remains mixed, with analysts highlighting both the company's recent positive earnings and the challenges it may face in the near future, leading to the bearish movement in the stock today.

04.01.2026 - LLY Stock was up 9.2%

• Eli Lilly's shares surged by 10% following the company's impressive fourth-quarter 2025 results and optimistic 2026 forecast, driven by the success of its weight-loss drugs Zepbound and Mounjaro.
• A Buy rating from Goldman Sachs for Eli Lilly further boosted investor confidence, highlighting the stock's attractiveness and maintaining a target price of USD 1145.
• The strong performance of Eli Lilly amidst a positive market reaction underscores the company's robust growth in the weight-loss drug market, setting a bullish tone for its future prospects.

04.01.2026 - LLY Stock was up 5.4%

• Eli Lilly reported impressive Q4 results, surpassing revenue and profit expectations, driven by the success of its drugs Zepbound and Mounjaro, leading to a significant stock surge.
• The company's robust 2026 revenue guidance, exceeding analyst estimates, indicates strong growth prospects and market confidence in its product pipeline.
• Positive market sentiment towards Eli Lilly contrasts with concerns in the pharmaceutical sector, highlighted by Pfizer's modest 2026 guidance and sustainability worries regarding its dividend payout ratio.
• Eli Lilly's performance showcases the importance of consistent innovation and successful product launches in driving stock value, setting it apart from competitors like Novo Nordisk.

04.01.2026 - LLY Stock was up 8.8%

• LLY's stock surged by 10% following the company's better-than-expected Q4 2025 results and optimistic 2026 forecast, driven by the success of weight-loss drugs Zepbound and Mounjaro.
• The positive market reaction can be attributed to Lilly's robust revenue growth of 42.6% year-over-year and adjusted earnings per share exceeding analyst estimates.
• This bullish trend for LLY contrasts with Novo Nordisk's recent 15% stock drop due to a conservative sales outlook, highlighting the importance of strong performance and growth forecasts in the pharmaceutical industry.
• Analysts, such as those at Goldman Sachs, continue to view Eli Lilly favorably, maintaining a Buy rating amidst the company's impressive financial results and market outlook.

09.01.2026 - LLY Stock was down 5.2%

• The acquisition of Orna by Eli Lilly for up to $2.4 billion may have stirred concerns among investors about potential risks and uncertainties related to the deal.
• Criticism from the FDA regarding Novo Nordisk's obesity pill advertisement, indirectly affecting competitors like Eli Lilly in the GLP-1 market, could have contributed to a negative sentiment in the sector.
• The market response to Pfizer's Q4 results, despite positive strides in its obesity drug segment, may have led to a broader bearish trend in the pharmaceutical industry, impacting stocks such as Eli Lilly.
• Eli Lilly's strategic shift towards diversification beyond obesity drugs through investments in circular RNA therapies could have triggered uncertainty among investors about the company's future direction and challenges in entering new markets.

09.01.2026 - LLY Stock was down 5.1%

• Eli Lilly's acquisition of Orna Therapeutics for up to $2.4 billion was met with mixed market sentiment, potentially contributing to the bearish movement.
• Despite the positive news of diversification into circular RNA therapies, investors may have concerns about the hefty price tag of the acquisition impacting Lilly's short-term financials.
• The market may be reacting to the broader industry news, such as Pfizer's lukewarm Q4 results and CVS Health Corporation facing pressure from proposed Medicare reimbursement rates, creating a cautious atmosphere for pharmaceutical stocks.
• Overall, while the acquisition signals Eli Lilly's strategic focus on expanding its portfolio, short-term market dynamics and industry challenges could be influencing the bearish trend in LLY stock.